Studies on the Mechanism of Telavancin Decreased Susceptibility in a Laboratory-Derived Mutant

Telavancin is a novel semi-synthetic lipoglycopeptide derivative of vancomycin with a dual mode of action. This study sought to understand knowledge of mechanisms of decreased susceptibility in laboratory-derived mutant. There were multiple significant changes in the transcriptome of TlvDSMED1952 indicating an altered overall physiology of the strain, likely decreased virulence, and changes in cell wall and membrane properties, probably due to multiple genetic changes in the strain. MHB cultures (biological replicates: N=3) were then grown to exponential phase (OD600=0.4). Dye-swapping was performed between samples.

特拉万星（Telavancin）是一类以万古霉素（vancomycin）为母核的新型半合成脂糖肽衍生物，具备双重作用机制。本研究旨在阐明实验室衍生突变株的耐药性降低机制。对TlVDSMED1952菌株的转录组（transcriptome）分析显示，该菌株的转录组存在多处显著表达差异，提示其整体生理状态发生改变，大概率伴随毒力减弱，同时细胞壁与细胞膜特性出现变化，这一现象大概率由该菌株的多重遗传变异所致。随后将穆勒-希顿肉汤（Mueller-Hinton Broth, MHB）培养物（生物学重复数N=3）培养至对数生长期（OD600=0.4），并在样本间开展染料互换实验。